|Table of Contents|

Research progress on biomarkers for predicting the efficacy of neoadjuvant therapy for muscle-invasive bladder cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 05
Page:
863-869
Research Field:
Publishing date:

Info

Title:
Research progress on biomarkers for predicting the efficacy of neoadjuvant therapy for muscle-invasive bladder cancer
Author(s):
LI Tao1; 2; QI Tianyu1; WU Kaijie1
1.Department of Urology,the First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China;2.Department of Urology,the First Hospital of Xi'an,Shaanxi Xi'an 710002,China.
Keywords:
muscle-invasive bladder cancer; neoadjuvant therapy; efficacy prediction; biomarker
PACS:
R737.14
DOI:
10.3969/j.issn.1672-4992.2025.05.022
Abstract:
For patients with muscle-invasive bladder cancer (MIBC),cystectomy is the gold standard in the treatment of local muscle-invasive bladder cancer,however,approximately 50% of patients develop metastases within 2 years of cystectomy and subsequently die from the disease.Cisplatin based neoadjuvant chemotherapy improves overall survival in patients with MIBC and is currently the recommended first-line treatment.In recent years,neoadjuvant immunotherapy for bladder cancer has shown remarkable results.However,some patients still do not benefit from neoadjuvant therapy and are at serious risk of drug toxicity and surgical delay.There is therefore a need for more accurate stratification of patients receiving neoadjuvant chemotherapy or neoadjuvant immunotherapy to identify patients who are more likely to respond.There is an unmet need to develop clinically reliable predictors of neoadjuvant therapy response.The aim of this paper is to review and summarize current biomarkers for predicting response to neoadjuvant therapy in muscle-invasive bladder cancer in order to provide more precise treatment.

References:

［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］ SIEGEL RL,GIAQUINTO AN,JEMAL A.Cancer statistics,2024［J］.CA Cancer J Clin,2024,74(1):12-49.
［3］ CZERNIAK B,DINNEY C,MCCONKEY D.Origins of bladder cancer［J］.Annu Rev Pathol,2016,11:149-174.
［4］ WITJES JA,BRUINS HM,CATHOMAS R,et al.European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer:summary of the 2020 guidelines［J］.Eur Urol,2021,79(1):82-104.
［5］ EULE CJ,WARREN A,MOLINA KUNA E,et al.Neoadjuvant cisplatin-based chemotherapy in nonmetastatic muscle-invasive bladder cancer:a systematic review and pooled meta-analysis to determine the preferred regimen［J］.Urology,2024,188:118-124.
［6］ CHRISTODOULEAS JP,BAUMANN BC,HE J,et al.Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710［J］.Cancer,2014,120(8):1272-1280.
［7］ FAHMY O,KHAIRUL-ASRI MG,SCHUBERT T,et al.A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer［J］.Urol Oncol,2018,36(2):43-53.
［8］ HUMPHREY PA,MOCH H,CUBILLA AL,et al.The 2016 WHO classification of tumours of the urinary system and male genital organs-part B:Prostate and bladder tumours［J］.Eur Urol,2016,70(1):106-119.
［9］ POKURI VK,SYED JR,YANG Z,et al.Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma［J］.Clin Genitourin Cancer,2016,14(1):e59-65.
［10］ HAJIRAN A,AZIZI M,AYDIN AM,et al.Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy［J］.J Urol,2021,205(1):100-108.
［11］ JAIN RK,SONPAVDE G.Neoadjuvant therapy for muscle-invasive bladder cancer［J］.Expert Rev Anticancer Ther,2020,20(7):603-614.
［12］ VETTERLEIN MW,WANKOWICZ SAM,SEISEN T,et al.Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology［J］.Cancer,2017,123(22):4346-4355.
［13］ MATULAY JT,WOLDU SL,LIM A,et al.The impact of squamous histology on survival in patients with muscle-invasive bladder cancer［J］.Urol Oncol,2019,37(6):353 e317-353 e324.
［14］ CHAKIRYAN NH,JIANG DD,GILLIS KA,et al.Pathological downstaging and survival outcomes associated with neoadjuvant chemotherapy for variant histology muscle invasive bladder cancer［J］.J Urol,2021,206(4):924-932.
［15］ TULPULE V,BALLAS LK.Concomitant systemic therapy:current and future perspectives［J］.Clin Oncol (R Coll Radiol),2021,33(6):e257-e263.
［16］ SCOSYREV E,ELY BW,MESSING EM,et al.Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)［J］.BJU Int,2011,108(5):693-699.
［17］ KAIMAKLIOTIS HZ,MONN MF,CHO JS,et al.Neoadjuvant chemotherapy in urothelial bladder cancer:impact of regimen and variant histology［J］.Future Oncol,2016,12(15):1795-1804.
［18］ MOSCHINI M,D'ANDREA D,KORN S,et al.Characteristics and clinical significance of histological variants of bladder cancer［J］.Nat Rev Urol,2017,14(11):651-668.
［19］ KAMOUN A,DE REYNIES A,ALLORY Y,et al.A consensus molecular classification of muscle-invasive bladder cancer［J］.Eur Urol,2020,77(4):420-433.
［20］ ROBERTSON AG,KIM J,AL-AHMADIE H,et al.Comprehensive molecular characterization of muscle-invasive bladder cancer［J］.Cell,2017,171(3):540-556.
［21］ SEILER R,ASHAB HAD,ERHO N,et al.Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy［J］.Eur Urol,2017,72(4):544-554.
［22］ SJODAHL G,ERIKSSON P,LIEDBERG F,et al.Molecular classification of urothelial carcinoma:global mRNA classification versus tumour-cell phenotype classification［J］.J Pathol,2017,242(1):113-125.
［23］ LERNER S，MCCONKEY D，TANGEN C，et al.Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized,muscle-invasive bladder cancer (SWOG S1314;NCT02177695)［J］.J Clin Oncol,2020(38):5028.
［24］ ESRIG D,ELMAJIAN D,GROSHEN S,et al.Accumulation of nuclear p53 and tumor progression in bladder cancer［J］.N Engl J Med,1994,331(19):1259-1264.
［25］ ZARGAR P,KOOCHAKKHANI S,HASSANZADEH M,et al.Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy［J］.Mol Biol Rep,2022,49(4):2755-2763.
［26］ XU J,PATEL NH,GEWIRTZ DA.Triangular relationship between p53,autophagy,and chemotherapy resistance［J］.Int J Mol Sci,2020,21(23):8991.
［27］ TSE J,GHANDOUR R,SINGLA N,et al.Molecular predictors of complete response following neoadjuvant chemotherapy in urothelial carcinoma of the bladder and upper tracts［J］.Int J Mol Sci,2019,20(4):793.
［28］ BURGESS EF,LIVASY C,TRUFAN S,et al.Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer［J］.Mol Clin Oncol,2022,16(5):102.
［29］ TCHELEBI L,ASHAMALLA H,GRAVES PR.Mutant p53 and the response to chemotherapy and radiation［J］.Subcell Biochem,2014,85:133-159.
［30］ TURKER P,SEGERSTEN U,MALMSTROM PU,et al.Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy［J］.Scand J Urol,2019,53(1):45-50.
［31］ POUREBRAHIMI E,MORADI TABRIZ H,MIRATASHI YAZDI SA,et al.The value of BCL2 and CK20 expression in predicting behavioral patterns of bladder cancer,a cross sectional study［J］.Ann Med Surg (Lond),2022,81:104372.
［32］ VAN ALLEN EM,MOUW KW,KIM P,et al.Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma［J］.Cancer Discov,2014,4(10):1140-1153.
［33］ LIU D,PLIMACK ER,HOFFMAN-CENSITS J,et al.Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma［J］.JAMA Oncol,2016,2(8):1094-1096.
［34］ PLIMACK ER,DUNBRACK RL,BRENNAN TA,et al.Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer［J］.Eur Urol,2015,68(6):959-967.
［35］ GROENENDIJK FH,DE JONG J,FRANSEN VAN DE PUTTE EE,et al.ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy［J］.Eur Urol,2016,69(3):384-388.
［36］ MOTTERLE G,ANDREWS JR,MORLACCO A,et al.Predicting response to neoadjuvant chemotherapy in bladder cancer［J］.Eur Urol Focus,2020,6(4):642-649.
［37］ PARDO JC,RUIZ DE PORRAS V,PLAJA A,et al.Moving towards personalized medicine in muscle-invasive bladder cancer:where are we now and where are we going［J］.Int J Mol Sci,2020,21(17):6271.
［38］ GAKIS G.Management of muscle-invasive bladder cancer in the 2020s:Challenges and perspectives［J］.Eur Urol Focus,2020,6(4):632-638.
［39］ CHANG SS.Re:Genomic differences between "primary" and "secondary" muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy［J］.J Urol,2019,202(1):30.
［40］ IYER G,BALAR AV,MILOWSKY MI,et al.Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer［J］.J Clin Oncol,2018,36(19):1949-1956.
［41］ BOXLEY P,PLETS M,FLAIG TW.Review of SWOG S1314:Lessons from a randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized,muscle-invasive bladder cancer［J］.Bladder Cancer,2020,6(2):123-129.
［42］ HEPBURN AC,LAZZARINI N,VEERATTERAPILLAY R,et al.Identification of CNGB1 as a predictor of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer［J］.Cancers (Basel),2021,13(15):3903.
［43］ LU YT,PLETS M,MORRISON G,et al.Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314［J］.Eur Urol Oncol,2023,6(5):516-524.
［44］ PAN J,LI X,WU W,et al.Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells［J］.Cancer Lett,2016,382(1):64-76.
［45］ LI Y,SHAN Z,LIU C,et al.MicroRNA-294 promotes cellular proliferation and motility through the PI3K/AKT and JAK/STAT pathways by upregulation of NRAS in bladder cancer［J］.Biochemistry (Mosc),2017,82(4):474-482.
［46］ ZHUANG J,SHEN L,YANG L,et al.TGFbeta1 promotes gemcitabine resistance through regulating the LncRNA-LET/NF90/miR-145 signaling axis in bladder cancer［J］.Theranostics,2017,7(12):3053-3067.
［47］ LIN SR,YEH HC,WANG WJ,et al.MiR-193b mediates CEBPD-induced cisplatin sensitization through targeting ETS1 and Cyclin D1 in human urothelial carcinoma cells［J］.J Cell Biochem,2017,118(6):1563-1573.
［48］ BAZARGANI ST,CLIFFORD TG,DJALADAT H,et al.Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer［J］.Urol Oncol,2019,37(1):1-11.
［49］ YAN S,ZENG H,JIN K,et al.NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer［J］.J Immunother Cancer,2022,10(5):e004569.
［50］ HU J,CHEN J,OU Z,et al.Neoadjuvant immunotherapy,chemotherapy,and combination therapy in muscle-invasive bladder cancer:A multi-center real-world retrospective study［J］.Cell Rep Med,2022,3(11):100785.
［51］ 战娜,徐君南,孙涛.肠道菌群与恶性肿瘤的研究进展［J］.现代肿瘤医学，2020,28(07):1202-1205. ZHAN Na,XU Junnan,SUN Tao.Advances in gastrointestinal microbiota and malignant tumor［J］.Modern Oncology,2020,28(07):1202-1205.
［52］ 焦倩倩,朱继伟,潘磊.肠道菌群与肺癌相关研究进展［J］.现代肿瘤医学，2024,32(3):569-576. JIAO Qianqian,ZHU Jiwei,PAN Lei.Research progress on the relationship between intestinal flora and lung cancer［J］.Modern Oncology,2024,32(3):569-576.
［53］ BROWN EM,CLARDY J,XAVIER RJ.Gut microbiome lipid metabolism and its impact on host physiology［J］.Cell Host Microbe,2023,31(2):173-186.
［54］ BUKAVINA L,GINWALA R,ELTOUKHI M,et al.Role of gut microbiome in neoadjuvant chemotherapy response in urothelial carcinoma:A multi-institutional prospective cohort evaluation［J］.Cancer Res Commun,2024,4(6):1505-1516.

Memo

Memo:
白求恩·泌尿肿瘤专项研究基金项目（编号：mnzl202010）
Last Update: 1900-01-01